The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trial.

BACKGROUND: Thrombolysis is of net benefit in patients with acute ischaemic stroke, who are younger than 80 years of age and are treated within 4·5 h of onset. The third International Stroke Trial (IST-3) sought to determine whether a wider range of patients might benefit up to 6 h from stroke onset...

Full description

Bibliographic Details
Main Authors: Sandercock, P, Wardlaw, J, Lindley, R, Dennis, M, Cohen, G, Murray, G, Innes, K, Venables, G, Czlonkowska, A, Kobayashi, A, Ricci, S, Murray, V, Berge, E, Slot, K, Hankey, G, Correia, M, Peeters, A, Matz, K, Lyrer, P, Gubitz, G, Phillips, S, Arauz, A
Format: Journal article
Language:English
Published: 2012

Similar Items